Open AccessThe Experience of Surfactant Therapy in Severe COVID-19 Pneumonia: A Case Report
Author(s) -
Igor Nikolaevich Banin,
A. V. Budnevsky,
Vyacheslav Grechkin,
Evgeniy Ovsyannikov,
Roman Tokmachev,
Oleg Neznamov,
I. A. Savushkina
Publication year - 2021
Publication title -
international journal of biomedicine
Language(s) - English
Resource type - Journals
eISSN - 2158-0529
pISSN - 2158-0510
DOI - 10.21103/article11(2)_cr1
Subject(s) - covid-19 , pulmonary surfactant , pneumonia , medicine , intensive care medicine , pandemic , mechanical ventilation , pathophysiology , perfusion , lung , pathology , disease , chemistry , outbreak , infectious disease (medical specialty) , biochemistry
The COVID-19 pandemic has presented challenges to finding effective treatment for lung damage. Medical researchers from different countries recognize the deficiency of pulmonary surfactant (PS) as a significant cause of the alveolar collapse, followed by microatelectasis and severe disturbances in the ventilation-perfusion relationship. Due to the pathophysiological rationale, experimental confirmations, and accumulated clinical experience, the PS preparations can be used to treat patients with severe COVID-19. The article provides a description of a case when ST was successfully used in a patient with severe COVID-19 pneumonia.